$JNJ, guidance and 2H commentary will set the tone for pharma and medtech; recall in 1Q, JNJ lowered revenue/EPS guidance to reflect COVID-19 impact in medtech business with expectations for recovery by 4Q in elective procedures and with minimal to no impact on  Pharma business